Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.

Autor: Rehman MB; Cardiology Department, Ramsay Santé, Médipôle Lyon-Villeurbanne, 158 rue Léon Blum, Villeurbanne, 69100, France. michaela.rehman@ramsaysante.fr., Tudrej BV; Université Claude Bernard Lyon 1, University College of General Medicine, 8 Avenue Rockefeller, Lyon, 69008, France.
Jazyk: angličtina
Zdroj: Lipids in health and disease [Lipids Health Dis] 2024 Sep 27; Vol. 23 (1), pp. 316. Date of Electronic Publication: 2024 Sep 27.
DOI: 10.1186/s12944-024-02307-6
Abstrakt: Background: Retention of apolipoprotein B (apoB)-containing lipoproteins within the arterial wall plays a major causal role in atherosclerotic cardiovascular disease (ASCVD). There is a single apoB molecule in all apoB-containing lipoproteins. Therefore, quantitation of apoB directly estimates the number of atherogenic particles in plasma. ApoB is the preferred measurement to refine the estimate of ASCVD risk. Low-density lipoprotein (LDL) particles are by far the most abundant apoB-containing particles. In patients with elevated lipoprotein(a) (Lp(a)), apoB may considerably underestimate risk because Mendelian randomization studies have shown that the atherogenicity of Lp(a) is approximately 7-fold greater than that of LDL on a per apoB particle basis. In subjects with increased Lp(a), the association between LDL-cholesterol and incident CHD (coronary heart disease) is increased, but the association between apoB and incident CHD is diminished or even lost. Thus, there is a need to understand the mechanisms of Lp(a), LDL-cholesterol and apoB-related CHD risk and to provide clinicians with a simple practical tool to address these complex and variable relationships. How can we understand a patient's overall lipid-driven atherogenic risk? What proportion of this risk does apoB capture? What proportion of this risk do Lp(a) particles carry? To answer these questions, we created a novel metric of atherogenic risk: risk-weighted apolipoprotein B.
Methods: In nmol/L: Risk-weighted apoB = apoB - Lp(a) + Lp(a) x 7 = apoB + Lp(a) x 6. Proportion of risk captured by apoB = apoB divided by risk-weighted apoB. Proportion of risk carried by Lp(a) = Lp(a) × 7 divided by risk-weighted apoB.
Results: Risk-weighted apoB agrees with risk estimation from large epidemiological studies and from several Mendelian randomization studies.
Conclusions: ApoB considerably underestimates risk in individuals with high Lp(a) levels. The association between apoB and incident CHD is diminished or even lost. These phenomena can be overcome and explained by risk-weighted apoB.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje